These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 35134204)

  • 1. Successful transition from intravenous epoprostenol to oral selexipag and inhaled iloprost in a case of severe pulmonary arterial hypertension associated with systemic lupus erythematosus.
    Saiki C; Kashiwado Y; Yokoyama T; Ayano M; Imabayashi K; Kawano S; Higashioka K; Kimoto Y; Fukata M; Mitoma H; Ono N; Arinobu Y; Akashi K; Horiuchi T; Niiro H
    Mod Rheumatol Case Rep; 2022 Jun; 6(2):183-188. PubMed ID: 35134204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful Management of Pregnancy in a Patient with Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension.
    Kawabe A; Nakano K; Aiko Y; Aramaki S; Onoue T; Okura D; Tanaka Y
    Intern Med; 2018 Jun; 57(11):1655-1659. PubMed ID: 29321410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to Selexipag.
    Verlinden NJ; Walter C; Raina A; Benza RL
    J Pharm Pract; 2021 Dec; 34(6):980-983. PubMed ID: 32912036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of systemic lupus erythematosus and pulmonary hypertension with intravenous prostaglandin I2 followed by its oral analogue.
    Ooiwa H; Miyazawa T; Yamanishi Y; Hiyama K; Ishioka S; Yamakido M
    Intern Med; 2000 Apr; 39(4):320-3. PubMed ID: 10801148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.
    Radosevich JJ; DeChristopher A; Irandost M; Fann J; Feldman J
    Am J Health Syst Pharm; 2020 Jul; 77(15):1208-1212. PubMed ID: 32620953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of immunosuppressants with bridge vasodilator therapy in severe lupus erythematosus-associated pulmonary arterial hypertension.
    Sanges S; Savale L; Lamblin N; Rémy-Jardin M; Humbert M; Sobanski V
    ESC Heart Fail; 2019 Dec; 6(6):1322-1325. PubMed ID: 31536678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
    Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
    J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report.
    Alexandre A; Furtado I; Carvalho L; Gonçalves F; Melo A; Alves J; Santos M; Reis A
    ESC Heart Fail; 2023 Aug; 10(4):2722-2727. PubMed ID: 37336527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary hypertension secondary to systemic lupus erythematosus: prolonged survival following treatment with intermittent low dose iloprost.
    Mok MY; Tse HF; Lau CS
    Lupus; 1999; 8(4):328-31. PubMed ID: 10413214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe pulmonary arterial hypertension and interstitial pneumonia related to systemic lupus erythematosus successfully treated with mycophenolate mofetil: A novel case report.
    Nawata M; Nagayasu A; Fujita Y; Nawata A; Saito K; Tanaka Y
    Lupus; 2020 Dec; 29(14):1955-1960. PubMed ID: 32914681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to pulmonary fibrosis].
    Olschewski H; Ghofrani HA; Walmrath D; Schermuly R; Temmesfeld-Wollbrück B; Grimminger F; Seeger W
    Pneumologie; 2000 Mar; 54(3):133-42. PubMed ID: 10783653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe pulmonary arterial hypertension and massive ascites in a patient with systemic lupus erythematosus and secondary Sjogren's syndrome.
    Yucel H; Vollmer O; Canuet M; Enache I; Kessler R; Korganow AS; Riou M
    Lupus; 2021 Mar; 30(3):510-513. PubMed ID: 33655792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perinatal Management and Long-Term Follow-up of a Primipara With Severe Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus.
    Song W; Chu S; Yang K; Sun X; Xia H; Mei C; Zhao Y; Wu J
    J Cardiothorac Vasc Anesth; 2022 Aug; 36(8 Pt A):2511-2517. PubMed ID: 34247927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognosis and management of reclassified systemic lupus erythematosus associated pulmonary arterial hypertension according to 2022 ESC/ERS guidelines.
    Li Y; Qian J; Dong X; Zhao J; Wang Q; Wang Y; Zeng X; Tian Z; Li M
    Arthritis Res Ther; 2024 May; 26(1):109. PubMed ID: 38802957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
    Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
    Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostacyclin for pulmonary arterial hypertension.
    Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
    Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe pulmonary hypertension in a patient with systemic lupus erythematosus and minimal lupus activity.
    Kawamura N; Tsutsui H; Fukuyama K; Hayashidani S; Koike G; Egashira K; Abe Y; Yamamoto H; Tsuneyoshi M; Takeshita A
    Intern Med; 2002 Feb; 41(2):109-12. PubMed ID: 11868596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
    Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
    Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent onset of acute lupus myocarditis, pulmonary arterial hypertension and digital gangrene in a lupus patient: a possible role of vasculitis to the rare disorders.
    Ando T; Yamasaki Y; Takakuwa Y; Iida H; Asari Y; Suzuki K; Uchida M; Kotoku N; Tanabe Y; Chosokabe M; Takahashi M; Suzuki K; Akashi YJ; Yamada H; Kawahata K
    Mod Rheumatol Case Rep; 2020 Jan; 4(1):21-27. PubMed ID: 33086967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.